학술논문

A Randomized Controlled Trial of Opt-In Versus Opt-Out Enrollment Into a Diabetes Behavioral Intervention.
Document Type
Journal Article
Source
American Journal of Health Promotion. Mar2018, Vol. 32 Issue 3, p745-752. 8p.
Subject
*PEOPLE with diabetes
*PATIENT compliance
*RANDOMIZED controlled trials
*HEALTH self-care
*TREATMENT of diabetes
*BEHAVIOR therapy
*BLOOD pressure
*COMPARATIVE studies
*RESEARCH methodology
*MEDICAL cooperation
*POPULATION
*PRIMARY health care
*RESEARCH
*STATISTICAL sampling
*SOCIOECONOMIC factors
*EVALUATION research
*BLIND experiment
*PATIENT selection
Language
ISSN
0890-1171
Abstract
Purpose: To examine the effect of an opt-out default recruitment strategy compared to a conventional opt-in strategy on enrollment and adherence to a behavioral intervention for poorly controlled diabetic patients.Design: Randomized controlled trial.Setting: University of Pennsylvania primary care practices.Participants: Participants of this trial included those with (1) age 18 to 80 years; (2) diabetes diagnosis; and (3) a measured hemoglobin A1c (HbA1c) greater than 8% in the past 12 months.Intervention: We randomized eligible patients into opt-in and opt-out arms prior to enrollment. Those in the opt-out arm received a letter stating that they were enrolled into a diabetes research study with the option to opt out, and those in the opt-in arm received a standard recruitment letter.Measures: Main end points include enrollment rate, defined as the proportion of participants who attended the baseline visit, and adherence to daily glycemic monitoring.Analysis: We powered our study to detect a 20% difference in adherence to device usage between arms and account for a 10% attrition rate.Results: Of the 569 eligible participants who received a recruitment letter, 496 were randomized to the opt-in arm and 73 to the opt-out arm. Enrollment rates were 38% in the opt-out arm and 13% in the opt-in arm ( P < .001).Conclusions: Opt-out defaults, where clinically appropriate, could be a useful approach for increasing the generalizability of low-risk trials testing behavioral interventions in clinical settings. [ABSTRACT FROM AUTHOR]